Skip to main content

Table 1 Dose levels

From: A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers

Level

Imatinib

Dacarbazine

Capecitabine

Patients (N)

Dose reductions (N)

DLTs1(N and type)

−1

300 mg

250 mg/m2

500 mg/m2 BID

6

0

1 (fatigue)

1

400 mg

250 mg/m2

500 mg/m2 BID

6

2

9 (Dyspnea, Fatigue, Diarrhea, Dehydration, Nausea, Ocular Surface Disease, Insomnia)

2

400 mg

330 mg/m2

750 mg/m2 BID

6

1

2 (Hypokalemia, platelets)

3

400 mg

330 mg/m2

1000 mg/m2 BID

0

0

 

4

600 mg

330 mg/m2

1000 mg/m2 BID

0

0

 

5

800 mg

330 mg/m2

1000 mg/m2 BID

0

0

 
  1. Dose levels specified for protocol therapy. 1: DLTs – dose-limiting toxicities.